dual anti-CD19 + anti-CD20 CAR T-cell therapy (Atara Biotherapeutics/Moffitt Cancer Center)

N/A

Report date: 2025/01/26 18:09:17

Base Information

Drug Namedual anti-CD19 + anti-CD20 CAR T-cell therapy (Atara Biotherapeutics/Moffitt Cancer Center)
Drug Alias NameCD19/CD20 bispecific CAR T-cell therapy (Atara Biotherapeutics/Moffitt Cancer Center)anti-CD19 + anti-CD20 CAR T-cell therapy (Atara Biotherapeutics/Moffitt Cancer Center)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsB-lymphocyte antigen CD20 modulators
TargetsB-lymphocyte antigen CD20B-lymphocyte antigen CD19
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesH Lee Moffitt Cancer Center & Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesAtara Biotherapeutics IncH Lee Moffitt Cancer Center & Research Institute
Inactive CompaniesN/A
Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A